Bipolar Disorder: Hospitalization Risks and Costs of Atypical Antipsychotics
Author Information
Author(s): Kim Edward, You Min, Pikalov Andrei, Van-Tran Quynh, Jing Yonghua
Primary Institution: Bristol-Myers Squibb
Hypothesis
What is the 1-year risk of psychiatric hospitalization and associated treatment costs in patients with bipolar disorder treated with atypical antipsychotics?
Conclusion
Treatment with aripiprazole was associated with a lower risk of psychiatric hospitalization and lower healthcare costs compared to other atypical antipsychotics.
Supporting Evidence
- Aripiprazole was associated with a lower risk of hospitalization compared to ziprasidone, olanzapine, and quetiapine.
- Mental health treatment costs were significantly lower for aripiprazole compared to ziprasidone and quetiapine.
- Total healthcare costs were significantly lower for aripiprazole compared to quetiapine.
Takeaway
This study found that people with bipolar disorder who took aripiprazole had fewer hospital visits and spent less money on treatment than those who took other similar medications.
Methodology
Retrospective cohort study using insurance claims data, following patients for up to 1 year after starting atypical antipsychotics.
Potential Biases
Potential for residual confounding despite propensity score matching.
Limitations
The study is non-randomized and may have unobserved treatment selection bias; results may not be applicable to all populations.
Participant Demographics
Outpatients aged 18-65 years with bipolar disorder.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website